The effects of nocturnal hemodialysis compared to conventional hemodialysis on change in left ventricular mass: Rationale and study design of a randomized controlled pilot study

BMC Nephrology

Volumn 7, Issue , 2006, Pages

  Walsh, Michael ^a   Manns, Braden J ^a,b,c   Klarenbach, Scott ^b,d   Quinn, Robert ^e   Tonelli, Marcello ^d   Culleton, Bruce F ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CANADA; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE MARKER; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; MINERAL METABOLISM; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

FEMALE; HEMODIALYSIS, HOME; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MULTICENTER STUDIES AS TOPIC; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; TIME FACTORS;

EID: 33646565298     PISSN: 14712369     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-7-2     Document Type: Article

References (31)

1. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998, 9:S16-S23.
2. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996, 11:1277-1285.
3. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989, 36:286-290.
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
5. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002, 347:2010-2019.
6. Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW, Ng FS, Cheng IK: Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 2003, 64:649-656.
7. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002, 13:1307-1320.
8. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
9. Gotch FA: The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998, 13 Suppl 6:10-4.:10-14.
10. Chan CT, Mardirossian S, Faratro R, Richardson RM: Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis 2003, 41:225-229.
11. Chan C, Floras JS, Miller JA, Pierratos A: Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 2002, 17:1518-1521.
12. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002, 61:2235-2239.
13. Heidenheim AP, Muirhead N, Moist L, Lindsay RM: Patient quality of life on quotidian hemodialysis. Am J Kidney Dis 2003, 42:36-41.
14. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA: The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int 2003, 64:1004-1011.
15. McPhatter LL, Lockridge RSJ, Albert J, Anderson H, Craft V, Jennings FM, Spencer M, Swafford A, Barger T, Coffey L: Nightly home hemodialysis: improvement in nutrition and quality of life. Adv Ren Replace Ther 1999, 6:358-365.
16. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS: Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003, 42:925-931.
17. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM: Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 2003, 42:13-17.
18. Alloatti S, Molino A, Manes M, Bonfant G, Pellu V: Long nocturnal dialysis. Blood Purif 2002, 20:525-530.
19. Schulman G: Daily hemodialysis: the time has come? - Con. Am J Kidney Dis 2005, 45:798-803.
20. Walsh M, Culleton B, Tonelli M, Manns B: A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005, 67:1500-1508.
21. Culleton BF, Gautam M, Peterson J, McVeigh E, Hons RB: Anemia management in dialysis patients is improved with a nurse managed algorithm [abstract]. J Am Soc Nephrol 2003, 14:s220-s220.
22. Horl MP, Horl WH: Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002, 39:227-244.
23. Hemmelgarn BR, McAllister FA, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Grover S, Honos G, Lebel M, Mann K, Wilson T, Penner B, Tremblay G, Tobe SW, Feldman RD: The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2005, 21:645-656.
24. Canadian Coordinating Office for Health Technology Assessment (CCOHTA): Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd Edition. Ottawa, Canada; 1997.
25. Korevaar JC, Merkus MP, Jansen MA, Dekker FW, Boeschoten EW, Krediet RT: Validation of the KDQOL-SF: a dialysis-targeted health measure. Qual Life Res 2002, 11:437-447.
26. Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C: Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 2003, 60:341-351.
27. Dolan P: Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108.
28. Kind P, Dolan P, Gudex C, Williams A: Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998, 316:736-741.
29. Wight JP, Edwards L, Brazier J, Walters S, Payne JN, Brown CB: The SF36 as an outcome measure of services for end stage renal failure. Qual Health Care 1998, 7:209-221.
30. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C: Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002, 40:611-622.
31. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995, 5:2024-2031.